Filing Flows › Korsana Biosciences (KRSA) › Q2 2025
Korsana Biosciences (KRSA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Korsana Biosciences (KRSA) reported revenue of $93K for the second quarter 2025 (Q2 2025) and +15% from the quarter before.
Korsana Biosciences, Q2 2025: revenue $93K, net loss $324K, operating cash flow −$503K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $93K | +15% | — |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$324K | — | — |
| Operating cash flow | −$503K | — | — |
What changed
Revenue was $93K in Q2 2025, up 15% from the previous quarter.
Operating costs exceeded revenue by $1.7M, an operating margin of -1797.8%. The quarter ended with a net loss of $324K, narrower than the previous quarter's $1.4M loss. Non-operating items added $1.3M, -416% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$503K. Non-cash charges added back $114K of share-based compensation. Working capital and other items used $293K.
Questions
What was Korsana Biosciences' revenue in the second quarter 2025?
Korsana Biosciences (KRSA) reported revenue of $93K for the second quarter 2025 (Q2 2025) and +15% from the quarter before.